Madrigal Pharmaceuticals (NASDAQ:MDGL) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, January 9th.
According to Zacks, “Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-ß agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-ß agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania. “
A number of other research firms have also recently weighed in on MDGL. Evercore ISI boosted their price objective on shares of Madrigal Pharmaceuticals from $65.00 to $140.00 and gave the company an “outperform” rating in a research report on Thursday, December 7th. Roth Capital boosted their price objective on shares of Madrigal Pharmaceuticals from $82.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, December 11th. JMP Securities boosted their price objective on shares of Madrigal Pharmaceuticals from $40.00 to $63.00 and gave the company an “outperform” rating in a research report on Friday, October 13th. Finally, HC Wainwright upped their price target on shares of Madrigal Pharmaceuticals from $54.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, December 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Madrigal Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $139.20.
Madrigal Pharmaceuticals (MDGL) opened at $147.99 on Tuesday. Madrigal Pharmaceuticals has a 1-year low of $13.09 and a 1-year high of $152.62. The company has a market cap of $2,070.00, a price-to-earnings ratio of -60.16 and a beta of 1.19.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.11. analysts anticipate that Madrigal Pharmaceuticals will post -2.57 earnings per share for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp lifted its stake in Madrigal Pharmaceuticals by 17.9% in the third quarter. Bank of New York Mellon Corp now owns 12,945 shares of the biopharmaceutical company’s stock worth $582,000 after acquiring an additional 1,963 shares during the period. SG Americas Securities LLC purchased a new stake in Madrigal Pharmaceuticals in the third quarter worth about $100,000. Strs Ohio lifted its stake in Madrigal Pharmaceuticals by 241.7% in the fourth quarter. Strs Ohio now owns 4,100 shares of the biopharmaceutical company’s stock worth $376,000 after acquiring an additional 2,900 shares during the period. New York State Common Retirement Fund purchased a new stake in Madrigal Pharmaceuticals in the second quarter worth about $109,000. Finally, JPMorgan Chase & Co. purchased a new stake in Madrigal Pharmaceuticals in the third quarter worth about $325,000. 19.08% of the stock is owned by institutional investors.
WARNING: “Madrigal Pharmaceuticals (MDGL) Lowered to “Hold” at Zacks Investment Research” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/05/madrigal-pharmaceuticals-mdgl-rating-lowered-to-hold-at-zacks-investment-research.html.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Get a free copy of the Zacks research report on Madrigal Pharmaceuticals (MDGL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.